Optimization of Idarubicin and Cytarabine Induction Regimen with Homoharringtonine for Newly Diagnosed AML Based on the Peripheral Blast Clearance Rate: First Result of the Multicenter, Randomized, Phase 3 Trial (RJ-AML 2016)
第一作者机构：[1]Shanghai Jiao Tong Univ, Ruijin Hosp, Shanghai Inst Hematol,Sch Med, State Key Lab Med Genom,Natl Res Ctr Translat Med, Shanghai, Peoples R China
推荐引用方式(GB/T 7714)：
Zhang Yunxiang,Chen Qiusheng,Weng Xiangqin,et al.Optimization of Idarubicin and Cytarabine Induction Regimen with Homoharringtonine for Newly Diagnosed AML Based on the Peripheral Blast Clearance Rate: First Result of the Multicenter, Randomized, Phase 3 Trial (RJ-AML 2016)[J].BLOOD.2023,142:doi:10.1182/blood-2023-179311.
APA：
Zhang, Yunxiang,Chen, Qiusheng,Weng, Xiangqin,Shen, Yang,Wu, Wen...&Li, Junmin.(2023).Optimization of Idarubicin and Cytarabine Induction Regimen with Homoharringtonine for Newly Diagnosed AML Based on the Peripheral Blast Clearance Rate: First Result of the Multicenter, Randomized, Phase 3 Trial (RJ-AML 2016).BLOOD,142,
MLA：
Zhang, Yunxiang,et al."Optimization of Idarubicin and Cytarabine Induction Regimen with Homoharringtonine for Newly Diagnosed AML Based on the Peripheral Blast Clearance Rate: First Result of the Multicenter, Randomized, Phase 3 Trial (RJ-AML 2016)".BLOOD 142.(2023)
医学